Pulmobiotics Highlights Nature Biotechnology Publication of Preclinical Data Demonstrating Clearance of Antibiotic-resistant Lung Infection
January 19, 2023 11:39 ET
|
Pulmobiotics, S.L.
-- First ‘living medicine’ to treat antibiotic-resistant Pseudomonas aeruginosa infections in the lung, a leading cause of mortality in hospital settings – -- Data demonstrate treatment reduced lung...
ContraFect Awarded Funding from CARB-X to Support Gram-Negative Lysin Program
March 30, 2017 11:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - March 30, 2017) - ContraFect Corporation (NASDAQ: CFRX), a biotechnology company focused on the discovery and development of protein and antibody therapeutics for...
ContraFect Announces Expanded Research Collaboration with The Rockefeller University to Identify Lysin Therapeutics Targeting Gram-negative Bacteria
November 14, 2016 07:00 ET
|
ContraFect Corporation
YONKERS, NY--(Marketwired - November 14, 2016) - ContraFect Corporation (NASDAQ: CFRX) (NASDAQ: CFRXW), a biotechnology company focused on the discovery and development of protein and antibody...